NgJacqi personal page - To The Moon

NgJacqi

NgJacqi

No personal profile

18Follow

1Followers

0Topic

0Badge

2021-09-19

Nice

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

2021-07-22

Oh

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

2021-07-16

Oh

Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.

2021-06-16

Mm

Bright Minds Biosciences Announces Application to List on Nasdaq

2021-05-25

[Smile]

Goldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%

2021-04-29

Mm

Here’s how Warren Buffett’s top investments fared during the pandemic

2021-04-29

.

Uber app in U.S. to enable users to book vaccines and rental cars

2021-04-22

H

Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3580907067323762","uuid":"3580907067323762","gmtCreate":1617813043092,"gmtModify":1619662698698,"name":"NgJacqi","pinyin":"ngjacqi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":18,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":887583775,"gmtCreate":1632064306797,"gmtModify":1676530694708,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887583775","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://ttm.financial/m/news/2153678132?lang=&edition=fundamental","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172623653,"gmtCreate":1626959806072,"gmtModify":1703481359298,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/172623653","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://ttm.financial/m/news/2153678132?lang=&edition=fundamental","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170402048,"gmtCreate":1626444496184,"gmtModify":1703760341551,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170402048","repostId":"1119997447","repostType":4,"repost":{"id":"1119997447","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626443027,"share":"https://ttm.financial/m/news/1119997447?lang=&edition=fundamental","pubTime":"2021-07-16 21:43","market":"us","language":"en","title":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.","url":"https://stock-news.laohu8.com/highlight/detail?id=1119997447","media":"Tiger Newspress","summary":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL s","content":"<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DAL":"达美航空","AAL":"美国航空","LUV":"西南航空","UAL":"联合大陆航空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119997447","content_text":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL shares rise more than 1%,AAL is up 0.5%.\nU.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.\n“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”\nHe said to expect an answer “within the next several days.”\nRemoving the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169587962,"gmtCreate":1623843384456,"gmtModify":1703821098356,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/169587962","repostId":"2143795927","repostType":4,"repost":{"id":"2143795927","pubTimestamp":1623840600,"share":"https://ttm.financial/m/news/2143795927?lang=&edition=fundamental","pubTime":"2021-06-16 18:50","market":"us","language":"en","title":"Bright Minds Biosciences Announces Application to List on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2143795927","media":"StreetInsider","summary":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Min","content":"<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”</p>\n<p>Commenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”</p>\n<p>In advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”</p>\n<p>Bright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.</p>\n<p>The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “<b>U.S. Securities Act</b>”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.</p>\n<p><b>About Bright Minds</b>Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bright Minds Biosciences Announces Application to List on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBright Minds Biosciences Announces Application to List on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18565519><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18565519\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QLD":"纳指两倍做多ETF","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF","QID":"纳指两倍做空ETF","NDAQ":"纳斯达克OMX交易所","BMBIF":"Bright Minds Biosciences Inc.",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18565519","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143795927","content_text":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”\nCommenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”\nIn advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”\nBright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.\nThe securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.\nAbout Bright MindsBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":131418321,"gmtCreate":1621873093863,"gmtModify":1704363724207,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/131418321","repostId":"2137153015","repostType":4,"repost":{"id":"2137153015","pubTimestamp":1621867734,"share":"https://ttm.financial/m/news/2137153015?lang=&edition=fundamental","pubTime":"2021-05-24 22:48","market":"us","language":"en","title":"Goldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2137153015","media":"TipRanks","summary":"Markets are beset by volatility, with unpredictable swings making recent sessions something of a rol","content":"<div>\n<p>Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RAIN":"RAIN ONCOLOGY INC","RLMD":"Relmada Therapeutics, Inc.","AGTI":"Agiliti, Inc.","GS":"高盛"},"source_url":"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137153015","content_text":"Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism – the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected.Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment.“The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months… equities will remain attractive relative to cash and bonds,” Kostin noted.Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firm’s analysts forecasting over 100% upside potential for each. Using TipRanks’ database, we found out that the rest of the Street is also on board, as each boasts a “Strong Buy” consensus rating.Rain Therapeutics (RAIN)We’ll start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is  still in preclinical trial.Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022.RAD52, the company’s second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year.As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds.Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: “While we’re optimistic on RAIN-32’s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32’s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts.”In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months.Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels.Relmada Therapeutics (RLMD)The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the company’s prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027.Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22.Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months.“We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date,” Tan opined.What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead.Agiliti (AGTI)We’ll close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment – along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites.On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO.Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last year’s Q1 net loss, and EPS was 9 cents per share.Looking at the company’s forward path, Goldman Sachs analyst Amit Hazan noted, “While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year.”Hazan summed up, \"We view AGTI’s end-to-end service model as differentiated and ideally suited in today’s Hospital operating environment; we see current valuation as an attractive entry point...”To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year.In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100439171,"gmtCreate":1619627192393,"gmtModify":1704727094553,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/100439171","repostId":"1104198438","repostType":4,"repost":{"id":"1104198438","pubTimestamp":1619623222,"share":"https://ttm.financial/m/news/1104198438?lang=&edition=fundamental","pubTime":"2021-04-28 23:20","market":"us","language":"en","title":"Here’s how Warren Buffett’s top investments fared during the pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1104198438","media":"Yahoo","summary":"Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to","content":"<p>Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.</p>\n<p>The famed stock portfolio run by billionaire investor Warren Buffett ballooned to a value of $281.17 billion by the end of 2020, or more than double the cumulative cost of building these stakes at $108.62 billion, according toBerkshire's latest annual shareholder letter.The value of the portfolio's total equity investments carried at market was up 13.4% compared to year-end 2019. However, Berkshire's own stock underperformed the broader market over that time period: The S&amp;P 500 rose 16.3% in 2020, without including reinvested dividends, while Berkshire's Class B shares increased 2.4%.</p>\n<p>Berkshire's stock performance in 2020 relative to the broader market, however, belies what has been, in aggregate, decades of outperformance for the Omaha, Nebraska-based company. Berkshire Hathaway's annual compounded gain between 1965 and 2020 was 20%, versus just 10.2% for the S&amp;P 500. And the firm's cumulative returns over that period have been a whopping 2,810,526% to the S&amp;P 500's 23,454%.</p>\n<p>On May 1, Buffett and long-time business partner Charlie Munger will hold Berkshire Hathaway's annual shareholder meeting in Los Angeles. This may serve as a forum for the pair to discuss additional investments purchased and sold in the first months of 2021, ahead of formal 13-F filing reveals later in the month. Last year, Buffett disclosed at the annual meeting thatBerkshire had sold out of its entire interest in the airline stocksAmerican Airlines (AAL), United Airlines (UAL), Delta Air Lines (DAL) and Southwest Airlines (LUV)in the first quarter of 2020.</p>\n<p>Here's how Berkshire's top 10 stock investments by market value fared over the course of the pandemic, based on the stakes disclosed in the Buffett's latest annual shareholder letter.*</p>\n<p><b>Apple</b></p>\n<p>Buffett pointed to Apple (AAPL) as one of the most valuable assets for Berkshire Hathaway alongside the firm's insurance operation and BNSF Railway, thanks in large part to the iPhone-maker's hefty share repurchases.</p>\n<p>Berkshire owned 907,559,761 shares of Apple as of the end of December for a total market value of $120.4 billion. By contrast, the firm spent just $31 billion accumulating this stake since late 2016.</p>\n<p>That massive holding — comprising 44% of Berkshire's disclosed assets, according to Bloomberg data — came even after the firm pocketed $11 billion after selling a small portion of its position in 2020.</p>\n<p>\"Despite that sale – voila! – Berkshire now owns 5.4% of Apple,\" Buffett said in the shareholder letter. \"That increase was costless to us,<b>coming about because Apple</b>has continuously repurchased its shares, thereby substantially shrinking the number it now has outstanding.\"</p>\n<p>Though Buffett hashistorically steered away from investing in technology companiesin favor of businesses he has understood more deeply, Berkshire's major holding in Apple proved auspicious during the pandemic, when Big Tech companies led the market higher.</p>\n<p>Apple's stock posted a total return of 82% in 2020, outperforming every other \"FAANG\" stock including Facebook, Amazon, Netflix and Alphabet. The run-up has since cooled in early 2021, however, with the stock posting a total return of just 1.4% for the year-to-date through market close on April 27.</p>\n<p><b>Bank of America</b></p>\n<p>While Berkshire Hathaway unloaded many of its bank stock holdings over the course of 2020, it increased its stake in Bank of America (BAC).</p>\n<p>The firm held 1,032,952,006 shares of Bank of America as of the end of 2020, after adding 85.1 million shares in the third quarter alone. This gave Berkshire Hathaway an ownership stake of 11.9%.</p>\n<p>By the end of last year, the value of that holding was worth $31.3 million, and cost $14.6 million to amass.</p>\n<p>The increase in the size of Berkshire Hathaway's Bank of America holding bucked the trend of the other bank stocks in the portfolio last year. Berkshire cut its holdings of Wells Fargo (EFC) from 345.7 million shares at year-end 2019 to 52.4 million by year-end 2020, and completely exited its holdings in JPMorgan Chase (JPM) and M&amp;T Bank Corp (MTB).</p>\n<p>With interest rates sliding amid ultra-accommodative monetary policy during the pandemic, bank stocks were among the worst performers last year. Bank of America shares fell nearly 14% in 2020, underperforming against both the S&amp;P 500 and S&amp;P 500 financials sector, which dropped just 4.1%. However, with interest rates back on the rise and consumer spending accelerating, shares have already started to reverse these declines, and Bank of America shares have risen 32% so far in 2021.</p>\n<p><b>The Coca-Cola Company</b></p>\n<p>Berkshire Hathaway's stake in Coca-Cola (KO) remained unchanged between 2019 and 2020 at 400 million shares, offering 9.3% ownership in the beverage giant. Buffett has been a long-time investor in the firm, having first purchased shares in Berkshire's portfolio in 1988. It has comprised a significant portion of the firm's total holdings and mark value value ever since.</p>\n<p>This long-term investment has paid off for the company, with the market value of the shares held totaling $21.9 billion at the end of 2020. Berkshire spent just under $1.3 billion building its stake in Coca-Cola.</p>\n<p>While Berkshire's overall return on its investment in Coca-Cola has been formidable, the stock did underperform the broader market in 2020. Coca-Cola shares declined 0.9% during the year as a dearth of live events and concessions weighed on sales, though the stock did still eke out a total return of 2.44% during the year with reinvested dividends. Shares have extended a run of underperformance in 2021, with the stock falling 1.5% so far this year.</p>\n<p><b>American Express</b></p>\n<p>Berkshire Hathaway held 151,610,700 shares of American Express (AXP) as of the end of 2020, with the stock comprising another of the firm's long-standing investments. Berkshire began building its stake nearly six decades ago, paying a total of just $1.29 billion to amass a stake worth $18.33 billion at the end of 2020.</p>\n<p>As a business relying heavily on both consumer and corporate spending, however, American Express' suffered a blow in 2020, with its stock dipping 2.9%.</p>\n<p>While Buffett has characterized Berkshire's holdings of marketable stocks as a \"collection of businesses\" in which he shares in long-term prosperity but does not control operations, that hasn't stopped him from imparting advice to executives at some of his top-held companies — especially during the nadir in business and economic activity during the pandemic.</p>\n<p>\"I talked to our largest shareholder, Warren Buffett, and I've talked to him during this time, the one thing he has and will continue to always point out to us is that the brand is special,\" American Express CEO Stephen Squeri said during an analyst day presentation in mid-March 2020. \"And that brand needs to be cared for, the brand needs to be invested in and we will continue to do so through tough times and through the good times.\"</p>\n<p>More recently, however, American Express's operating results and stock have picked back up. The stock outperformed the S&amp;P 500 with a rise of 25% for the year-to-date. And Squeri saidin a fourth-quarter updatethat non-travel and entertainment spend exceeded pre-COVID levels for a second straight quarter, and that trends overall have \"continued to steadily improve,\" despite some lingering impacts from the pandemic.</p>\n<p><b>Verizon Communications</b></p>\n<p>Verizon Communications (VZ), the parent company of Yahoo Finance, was one of Berkshire's new purchases in the second half of 2020.</p>\n<p>Berkshire revealed it amassed a stake of 146,716,496 shares of the telecommunications giant last year, good for a 3.5% ownership of the company.</p>\n<p>The holding was worth $8.62 billion as of year-end, representing one of several major investments Berkshire held below cost, which in this case came in at $8.69 billion. The decline likely would have been greater had Berkshire purchased the sizable stake earlier, however, with Verizon's stock having declined 4.3% excluding reinvested dividends over the the full-year 2020.</p>\n<p>But even given the pandemic, Verizon's business held up relatively strongly. Full-year 2020 sales edged down by just 3%, and adjusted EBITDA was flat year-over-year. Still, the stock has declined by 4% for 2021-to-date, or by 2% with reinvested dividends.</p>\n<p><b>Moody's Corporation</b></p>\n<p>Berkshire Hathaway had a 13.2% ownership stake in Moody's Corporation (MCO) at the end of 2020, with 24,669,778 shares worth a total of $7.16 billion. That generated a notable return for Berkshire, with the cost of building this stake amounting to just $248 million. Berkshire first held shares of Moody's Corporation in 2000.</p>\n<p>The credit rating agency outperformed the S&amp;P 500 in 2020 and has since performed about in-line with the market during the COVID-19 recovery. Shares rose by 22% over the course of 2020 and have increased by 12.5% for the year-to-date.</p>\n<p><b>U.S. Bancorp</b></p>\n<p>U.S. Bancorp (USB) was one of a number of holdings Berkshire Hathaway trimmed during the pandemic.</p>\n<p>The firm's stake in the parent company of U.S. Bank National Association was reduced to 148,176,166 shares by year-end 2020, compared to 149,497,787 in 2019. However, Berkshire Hathaway stopped short of fully exiting its position in the firm, as it did with some other big banks. Berkshire's position in U.S. Bancorp was worth just over $6.9 billion in year-end 2020, compared to total cost of $5.6 billion.</p>\n<p>As was the case for many financial institutions during the pandemic, U.S. Bancorp's stock came under pressure in the low-rate environment of 2020, but has since rebounded. Shares slid by 21.4% in 2020, but have so far risen more than 25% for the year-to-date.</p>\n<p><b>BYD</b></p>\n<p>Shenzhen-based BYD Co. (BYDDF) marks one of just a couple non-U.S. companies in Berkshire Hathaway's portfolio as of the end of 2020. The electric-vehicle manufacturer's stock was also the best-performing in Berkshire's portfolio during the pandemic on a price-appreciation basis, consistent with the outperformance among tech and growth stocks seen over the course of last year in the broader market. In fact, the market value of Berkshire's BYD Co. stake was more than double that of its other major auto-related position in General Motors (GM).</p>\n<p>Berkshire purchased the entirety of his 225 million share stake in BYD back in 2008 for $232 million, afterBuffett's business partner Charlie Munger toutedthe vision of its founder Wang Chuanfu. The value of that stake ballooned to $5.9 billion at the end of 2020. Shares of BYD surged by 432% in 2020 alone, though they have dipped by 13.5% for the year-to-date as some of the exuberance around electric-vehicle stocks moderated at the start of this year.</p>\n<p><b>Chevron</b></p>\n<p>Berkshire Hathaway pounced at the opportunity to purchase Chevron (CVX) during a dip in oil prices and energy stocks last year, snapping up 48,498,965 million shares at a total cost of $4.02 billion. This represented 2.5% of shares outstanding for the stock.</p>\n<p>By year-end, the market value of Berkshire's stake increased slightly to about $4.1 billion, with energy prices back on the rise following the worst points of spring 2020. Chevron's stock slid 30% between year-end 2019 and year-end 2020.</p>\n<p>Berkshire's investment has already begun to appreciate in value in the early months of 2021, with energy as the best-performing sector in the S&amp;P 500 for the year-to-date. Chevron shares have risen 21.6% so far this year for a price appreciation nearly double that of the broader market, not including reinvested dividends.</p>\n<p><b>Charter Communications</b></p>\n<p>Charter Communications (CHTR) marked another holding Berkshire Hathaway trimmed in 2020. In August of last year, Berkshire reported it had cut its stake by 4% to a total of about 5.2 million shares.</p>\n<p>The sale still left Berkshire with a 2.7% stake in the company, and holdings worth $3.45 billion by year-end 2020, at a total cost of just $904 million. Berkshire had beenaccumulating its stake in Charter since 2014.</p>\n<p>Shares of Charter Communications rose 36% in 2020, but have given back some of these gains after dipping 1.2% so far in 2021.</p>\n<p><i>* This analysis excludes Berkshire Hathaway's Kraft Heinz holding of 325,442,152 shares, since this is held using a different accounting method. Berkshire reported that the market value of these shares was $11.3 billion as of December 31, 2020.</i></p>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s how Warren Buffett’s top investments fared during the pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s how Warren Buffett’s top investments fared during the pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html><strong>Yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.\nThe famed stock portfolio run by billionaire investor Warren Buffett ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVX":"雪佛龙","KO":"可口可乐","002594":"比亚迪","MCO":"穆迪","BAC":"美国银行","CHTR":"特许通讯","01211":"比亚迪股份","VZ":"威瑞森","USB":"美国合众银行","AXP":"美国运通","AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104198438","content_text":"Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.\nThe famed stock portfolio run by billionaire investor Warren Buffett ballooned to a value of $281.17 billion by the end of 2020, or more than double the cumulative cost of building these stakes at $108.62 billion, according toBerkshire's latest annual shareholder letter.The value of the portfolio's total equity investments carried at market was up 13.4% compared to year-end 2019. However, Berkshire's own stock underperformed the broader market over that time period: The S&P 500 rose 16.3% in 2020, without including reinvested dividends, while Berkshire's Class B shares increased 2.4%.\nBerkshire's stock performance in 2020 relative to the broader market, however, belies what has been, in aggregate, decades of outperformance for the Omaha, Nebraska-based company. Berkshire Hathaway's annual compounded gain between 1965 and 2020 was 20%, versus just 10.2% for the S&P 500. And the firm's cumulative returns over that period have been a whopping 2,810,526% to the S&P 500's 23,454%.\nOn May 1, Buffett and long-time business partner Charlie Munger will hold Berkshire Hathaway's annual shareholder meeting in Los Angeles. This may serve as a forum for the pair to discuss additional investments purchased and sold in the first months of 2021, ahead of formal 13-F filing reveals later in the month. Last year, Buffett disclosed at the annual meeting thatBerkshire had sold out of its entire interest in the airline stocksAmerican Airlines (AAL), United Airlines (UAL), Delta Air Lines (DAL) and Southwest Airlines (LUV)in the first quarter of 2020.\nHere's how Berkshire's top 10 stock investments by market value fared over the course of the pandemic, based on the stakes disclosed in the Buffett's latest annual shareholder letter.*\nApple\nBuffett pointed to Apple (AAPL) as one of the most valuable assets for Berkshire Hathaway alongside the firm's insurance operation and BNSF Railway, thanks in large part to the iPhone-maker's hefty share repurchases.\nBerkshire owned 907,559,761 shares of Apple as of the end of December for a total market value of $120.4 billion. By contrast, the firm spent just $31 billion accumulating this stake since late 2016.\nThat massive holding — comprising 44% of Berkshire's disclosed assets, according to Bloomberg data — came even after the firm pocketed $11 billion after selling a small portion of its position in 2020.\n\"Despite that sale – voila! – Berkshire now owns 5.4% of Apple,\" Buffett said in the shareholder letter. \"That increase was costless to us,coming about because Applehas continuously repurchased its shares, thereby substantially shrinking the number it now has outstanding.\"\nThough Buffett hashistorically steered away from investing in technology companiesin favor of businesses he has understood more deeply, Berkshire's major holding in Apple proved auspicious during the pandemic, when Big Tech companies led the market higher.\nApple's stock posted a total return of 82% in 2020, outperforming every other \"FAANG\" stock including Facebook, Amazon, Netflix and Alphabet. The run-up has since cooled in early 2021, however, with the stock posting a total return of just 1.4% for the year-to-date through market close on April 27.\nBank of America\nWhile Berkshire Hathaway unloaded many of its bank stock holdings over the course of 2020, it increased its stake in Bank of America (BAC).\nThe firm held 1,032,952,006 shares of Bank of America as of the end of 2020, after adding 85.1 million shares in the third quarter alone. This gave Berkshire Hathaway an ownership stake of 11.9%.\nBy the end of last year, the value of that holding was worth $31.3 million, and cost $14.6 million to amass.\nThe increase in the size of Berkshire Hathaway's Bank of America holding bucked the trend of the other bank stocks in the portfolio last year. Berkshire cut its holdings of Wells Fargo (EFC) from 345.7 million shares at year-end 2019 to 52.4 million by year-end 2020, and completely exited its holdings in JPMorgan Chase (JPM) and M&T Bank Corp (MTB).\nWith interest rates sliding amid ultra-accommodative monetary policy during the pandemic, bank stocks were among the worst performers last year. Bank of America shares fell nearly 14% in 2020, underperforming against both the S&P 500 and S&P 500 financials sector, which dropped just 4.1%. However, with interest rates back on the rise and consumer spending accelerating, shares have already started to reverse these declines, and Bank of America shares have risen 32% so far in 2021.\nThe Coca-Cola Company\nBerkshire Hathaway's stake in Coca-Cola (KO) remained unchanged between 2019 and 2020 at 400 million shares, offering 9.3% ownership in the beverage giant. Buffett has been a long-time investor in the firm, having first purchased shares in Berkshire's portfolio in 1988. It has comprised a significant portion of the firm's total holdings and mark value value ever since.\nThis long-term investment has paid off for the company, with the market value of the shares held totaling $21.9 billion at the end of 2020. Berkshire spent just under $1.3 billion building its stake in Coca-Cola.\nWhile Berkshire's overall return on its investment in Coca-Cola has been formidable, the stock did underperform the broader market in 2020. Coca-Cola shares declined 0.9% during the year as a dearth of live events and concessions weighed on sales, though the stock did still eke out a total return of 2.44% during the year with reinvested dividends. Shares have extended a run of underperformance in 2021, with the stock falling 1.5% so far this year.\nAmerican Express\nBerkshire Hathaway held 151,610,700 shares of American Express (AXP) as of the end of 2020, with the stock comprising another of the firm's long-standing investments. Berkshire began building its stake nearly six decades ago, paying a total of just $1.29 billion to amass a stake worth $18.33 billion at the end of 2020.\nAs a business relying heavily on both consumer and corporate spending, however, American Express' suffered a blow in 2020, with its stock dipping 2.9%.\nWhile Buffett has characterized Berkshire's holdings of marketable stocks as a \"collection of businesses\" in which he shares in long-term prosperity but does not control operations, that hasn't stopped him from imparting advice to executives at some of his top-held companies — especially during the nadir in business and economic activity during the pandemic.\n\"I talked to our largest shareholder, Warren Buffett, and I've talked to him during this time, the one thing he has and will continue to always point out to us is that the brand is special,\" American Express CEO Stephen Squeri said during an analyst day presentation in mid-March 2020. \"And that brand needs to be cared for, the brand needs to be invested in and we will continue to do so through tough times and through the good times.\"\nMore recently, however, American Express's operating results and stock have picked back up. The stock outperformed the S&P 500 with a rise of 25% for the year-to-date. And Squeri saidin a fourth-quarter updatethat non-travel and entertainment spend exceeded pre-COVID levels for a second straight quarter, and that trends overall have \"continued to steadily improve,\" despite some lingering impacts from the pandemic.\nVerizon Communications\nVerizon Communications (VZ), the parent company of Yahoo Finance, was one of Berkshire's new purchases in the second half of 2020.\nBerkshire revealed it amassed a stake of 146,716,496 shares of the telecommunications giant last year, good for a 3.5% ownership of the company.\nThe holding was worth $8.62 billion as of year-end, representing one of several major investments Berkshire held below cost, which in this case came in at $8.69 billion. The decline likely would have been greater had Berkshire purchased the sizable stake earlier, however, with Verizon's stock having declined 4.3% excluding reinvested dividends over the the full-year 2020.\nBut even given the pandemic, Verizon's business held up relatively strongly. Full-year 2020 sales edged down by just 3%, and adjusted EBITDA was flat year-over-year. Still, the stock has declined by 4% for 2021-to-date, or by 2% with reinvested dividends.\nMoody's Corporation\nBerkshire Hathaway had a 13.2% ownership stake in Moody's Corporation (MCO) at the end of 2020, with 24,669,778 shares worth a total of $7.16 billion. That generated a notable return for Berkshire, with the cost of building this stake amounting to just $248 million. Berkshire first held shares of Moody's Corporation in 2000.\nThe credit rating agency outperformed the S&P 500 in 2020 and has since performed about in-line with the market during the COVID-19 recovery. Shares rose by 22% over the course of 2020 and have increased by 12.5% for the year-to-date.\nU.S. Bancorp\nU.S. Bancorp (USB) was one of a number of holdings Berkshire Hathaway trimmed during the pandemic.\nThe firm's stake in the parent company of U.S. Bank National Association was reduced to 148,176,166 shares by year-end 2020, compared to 149,497,787 in 2019. However, Berkshire Hathaway stopped short of fully exiting its position in the firm, as it did with some other big banks. Berkshire's position in U.S. Bancorp was worth just over $6.9 billion in year-end 2020, compared to total cost of $5.6 billion.\nAs was the case for many financial institutions during the pandemic, U.S. Bancorp's stock came under pressure in the low-rate environment of 2020, but has since rebounded. Shares slid by 21.4% in 2020, but have so far risen more than 25% for the year-to-date.\nBYD\nShenzhen-based BYD Co. (BYDDF) marks one of just a couple non-U.S. companies in Berkshire Hathaway's portfolio as of the end of 2020. The electric-vehicle manufacturer's stock was also the best-performing in Berkshire's portfolio during the pandemic on a price-appreciation basis, consistent with the outperformance among tech and growth stocks seen over the course of last year in the broader market. In fact, the market value of Berkshire's BYD Co. stake was more than double that of its other major auto-related position in General Motors (GM).\nBerkshire purchased the entirety of his 225 million share stake in BYD back in 2008 for $232 million, afterBuffett's business partner Charlie Munger toutedthe vision of its founder Wang Chuanfu. The value of that stake ballooned to $5.9 billion at the end of 2020. Shares of BYD surged by 432% in 2020 alone, though they have dipped by 13.5% for the year-to-date as some of the exuberance around electric-vehicle stocks moderated at the start of this year.\nChevron\nBerkshire Hathaway pounced at the opportunity to purchase Chevron (CVX) during a dip in oil prices and energy stocks last year, snapping up 48,498,965 million shares at a total cost of $4.02 billion. This represented 2.5% of shares outstanding for the stock.\nBy year-end, the market value of Berkshire's stake increased slightly to about $4.1 billion, with energy prices back on the rise following the worst points of spring 2020. Chevron's stock slid 30% between year-end 2019 and year-end 2020.\nBerkshire's investment has already begun to appreciate in value in the early months of 2021, with energy as the best-performing sector in the S&P 500 for the year-to-date. Chevron shares have risen 21.6% so far this year for a price appreciation nearly double that of the broader market, not including reinvested dividends.\nCharter Communications\nCharter Communications (CHTR) marked another holding Berkshire Hathaway trimmed in 2020. In August of last year, Berkshire reported it had cut its stake by 4% to a total of about 5.2 million shares.\nThe sale still left Berkshire with a 2.7% stake in the company, and holdings worth $3.45 billion by year-end 2020, at a total cost of just $904 million. Berkshire had beenaccumulating its stake in Charter since 2014.\nShares of Charter Communications rose 36% in 2020, but have given back some of these gains after dipping 1.2% so far in 2021.\n* This analysis excludes Berkshire Hathaway's Kraft Heinz holding of 325,442,152 shares, since this is held using a different accounting method. Berkshire reported that the market value of these shares was $11.3 billion as of December 31, 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100430961,"gmtCreate":1619627089353,"gmtModify":1704727092931,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/100430961","repostId":"1196474090","repostType":4,"repost":{"id":"1196474090","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619623392,"share":"https://ttm.financial/m/news/1196474090?lang=&edition=fundamental","pubTime":"2021-04-28 23:23","market":"us","language":"en","title":"Uber app in U.S. to enable users to book vaccines and rental cars","url":"https://stock-news.laohu8.com/highlight/detail?id=1196474090","media":"Reuters","summary":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. custo","content":"<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber app in U.S. to enable users to book vaccines and rental cars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber app in U.S. to enable users to book vaccines and rental cars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-28 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196474090","content_text":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.\nCustomers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.\nThe feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.\nFor Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.\nThe company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.\nFrom Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.\nIn May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.\nUber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.\nUber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.","news_type":1},"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376955276,"gmtCreate":1619083157295,"gmtModify":1704719364539,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/376955276","repostId":"1134663439","repostType":4,"repost":{"id":"1134663439","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619082614,"share":"https://ttm.financial/m/news/1134663439?lang=&edition=fundamental","pubTime":"2021-04-22 17:10","market":"us","language":"en","title":"Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1134663439","media":"Benzinga","summary":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have team","content":"<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-22 17:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SQ":"Block"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134663439","content_text":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.What Happened: Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.Square is heavily invested in Bitcoin. Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchangeCoinbase Global Inc.(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.Why It Matters: The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation.Bank of America analyst Francisco Blanchcriticized Bitcoin in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.Microsoft Corporation (NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":169587962,"gmtCreate":1623843384456,"gmtModify":1703821098356,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/169587962","repostId":"2143795927","repostType":4,"repost":{"id":"2143795927","pubTimestamp":1623840600,"share":"https://ttm.financial/m/news/2143795927?lang=&edition=fundamental","pubTime":"2021-06-16 18:50","market":"us","language":"en","title":"Bright Minds Biosciences Announces Application to List on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2143795927","media":"StreetInsider","summary":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Min","content":"<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”</p>\n<p>Commenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”</p>\n<p>In advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”</p>\n<p>Bright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.</p>\n<p>The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “<b>U.S. Securities Act</b>”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.</p>\n<p><b>About Bright Minds</b>Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bright Minds Biosciences Announces Application to List on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBright Minds Biosciences Announces Application to List on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18565519><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18565519\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QLD":"纳指两倍做多ETF","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF","QID":"纳指两倍做空ETF","NDAQ":"纳斯达克OMX交易所","BMBIF":"Bright Minds Biosciences Inc.",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18565519","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143795927","content_text":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”\nCommenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”\nIn advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”\nBright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.\nThe securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.\nAbout Bright MindsBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172623653,"gmtCreate":1626959806072,"gmtModify":1703481359298,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/172623653","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://ttm.financial/m/news/2153678132?lang=&edition=fundamental","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170402048,"gmtCreate":1626444496184,"gmtModify":1703760341551,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170402048","repostId":"1119997447","repostType":4,"repost":{"id":"1119997447","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626443027,"share":"https://ttm.financial/m/news/1119997447?lang=&edition=fundamental","pubTime":"2021-07-16 21:43","market":"us","language":"en","title":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.","url":"https://stock-news.laohu8.com/highlight/detail?id=1119997447","media":"Tiger Newspress","summary":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL s","content":"<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DAL":"达美航空","AAL":"美国航空","LUV":"西南航空","UAL":"联合大陆航空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119997447","content_text":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL shares rise more than 1%,AAL is up 0.5%.\nU.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.\n“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”\nHe said to expect an answer “within the next several days.”\nRemoving the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":131418321,"gmtCreate":1621873093863,"gmtModify":1704363724207,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/131418321","repostId":"2137153015","repostType":4,"repost":{"id":"2137153015","pubTimestamp":1621867734,"share":"https://ttm.financial/m/news/2137153015?lang=&edition=fundamental","pubTime":"2021-05-24 22:48","market":"us","language":"en","title":"Goldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2137153015","media":"TipRanks","summary":"Markets are beset by volatility, with unpredictable swings making recent sessions something of a rol","content":"<div>\n<p>Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs: These 3 Stocks Are Poised to Surge by Over 100%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RAIN":"RAIN ONCOLOGY INC","RLMD":"Relmada Therapeutics, Inc.","AGTI":"Agiliti, Inc.","GS":"高盛"},"source_url":"https://finance.yahoo.com/news/goldman-sachs-3-stocks-poised-141954536.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137153015","content_text":"Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism – the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected.Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment.“The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth... U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months… equities will remain attractive relative to cash and bonds,” Kostin noted.Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firm’s analysts forecasting over 100% upside potential for each. Using TipRanks’ database, we found out that the rest of the Street is also on board, as each boasts a “Strong Buy” consensus rating.Rain Therapeutics (RAIN)We’ll start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is  still in preclinical trial.Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022.RAD52, the company’s second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year.As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds.Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: “While we’re optimistic on RAIN-32’s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32’s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts.”In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months.Turning now to the rest of the Street, other analysts echo Suvannavejh's sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels.Relmada Therapeutics (RLMD)The next stock on Goldman Sachs's radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the company’s prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027.Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22.Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months.“We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date,” Tan opined.What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead.Agiliti (AGTI)We’ll close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment – along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites.On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO.Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last year’s Q1 net loss, and EPS was 9 cents per share.Looking at the company’s forward path, Goldman Sachs analyst Amit Hazan noted, “While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year.”Hazan summed up, \"We view AGTI’s end-to-end service model as differentiated and ideally suited in today’s Hospital operating environment; we see current valuation as an attractive entry point...”To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year.In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100439171,"gmtCreate":1619627192393,"gmtModify":1704727094553,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/100439171","repostId":"1104198438","repostType":4,"repost":{"id":"1104198438","pubTimestamp":1619623222,"share":"https://ttm.financial/m/news/1104198438?lang=&edition=fundamental","pubTime":"2021-04-28 23:20","market":"us","language":"en","title":"Here’s how Warren Buffett’s top investments fared during the pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=1104198438","media":"Yahoo","summary":"Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to","content":"<p>Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.</p>\n<p>The famed stock portfolio run by billionaire investor Warren Buffett ballooned to a value of $281.17 billion by the end of 2020, or more than double the cumulative cost of building these stakes at $108.62 billion, according toBerkshire's latest annual shareholder letter.The value of the portfolio's total equity investments carried at market was up 13.4% compared to year-end 2019. However, Berkshire's own stock underperformed the broader market over that time period: The S&amp;P 500 rose 16.3% in 2020, without including reinvested dividends, while Berkshire's Class B shares increased 2.4%.</p>\n<p>Berkshire's stock performance in 2020 relative to the broader market, however, belies what has been, in aggregate, decades of outperformance for the Omaha, Nebraska-based company. Berkshire Hathaway's annual compounded gain between 1965 and 2020 was 20%, versus just 10.2% for the S&amp;P 500. And the firm's cumulative returns over that period have been a whopping 2,810,526% to the S&amp;P 500's 23,454%.</p>\n<p>On May 1, Buffett and long-time business partner Charlie Munger will hold Berkshire Hathaway's annual shareholder meeting in Los Angeles. This may serve as a forum for the pair to discuss additional investments purchased and sold in the first months of 2021, ahead of formal 13-F filing reveals later in the month. Last year, Buffett disclosed at the annual meeting thatBerkshire had sold out of its entire interest in the airline stocksAmerican Airlines (AAL), United Airlines (UAL), Delta Air Lines (DAL) and Southwest Airlines (LUV)in the first quarter of 2020.</p>\n<p>Here's how Berkshire's top 10 stock investments by market value fared over the course of the pandemic, based on the stakes disclosed in the Buffett's latest annual shareholder letter.*</p>\n<p><b>Apple</b></p>\n<p>Buffett pointed to Apple (AAPL) as one of the most valuable assets for Berkshire Hathaway alongside the firm's insurance operation and BNSF Railway, thanks in large part to the iPhone-maker's hefty share repurchases.</p>\n<p>Berkshire owned 907,559,761 shares of Apple as of the end of December for a total market value of $120.4 billion. By contrast, the firm spent just $31 billion accumulating this stake since late 2016.</p>\n<p>That massive holding — comprising 44% of Berkshire's disclosed assets, according to Bloomberg data — came even after the firm pocketed $11 billion after selling a small portion of its position in 2020.</p>\n<p>\"Despite that sale – voila! – Berkshire now owns 5.4% of Apple,\" Buffett said in the shareholder letter. \"That increase was costless to us,<b>coming about because Apple</b>has continuously repurchased its shares, thereby substantially shrinking the number it now has outstanding.\"</p>\n<p>Though Buffett hashistorically steered away from investing in technology companiesin favor of businesses he has understood more deeply, Berkshire's major holding in Apple proved auspicious during the pandemic, when Big Tech companies led the market higher.</p>\n<p>Apple's stock posted a total return of 82% in 2020, outperforming every other \"FAANG\" stock including Facebook, Amazon, Netflix and Alphabet. The run-up has since cooled in early 2021, however, with the stock posting a total return of just 1.4% for the year-to-date through market close on April 27.</p>\n<p><b>Bank of America</b></p>\n<p>While Berkshire Hathaway unloaded many of its bank stock holdings over the course of 2020, it increased its stake in Bank of America (BAC).</p>\n<p>The firm held 1,032,952,006 shares of Bank of America as of the end of 2020, after adding 85.1 million shares in the third quarter alone. This gave Berkshire Hathaway an ownership stake of 11.9%.</p>\n<p>By the end of last year, the value of that holding was worth $31.3 million, and cost $14.6 million to amass.</p>\n<p>The increase in the size of Berkshire Hathaway's Bank of America holding bucked the trend of the other bank stocks in the portfolio last year. Berkshire cut its holdings of Wells Fargo (EFC) from 345.7 million shares at year-end 2019 to 52.4 million by year-end 2020, and completely exited its holdings in JPMorgan Chase (JPM) and M&amp;T Bank Corp (MTB).</p>\n<p>With interest rates sliding amid ultra-accommodative monetary policy during the pandemic, bank stocks were among the worst performers last year. Bank of America shares fell nearly 14% in 2020, underperforming against both the S&amp;P 500 and S&amp;P 500 financials sector, which dropped just 4.1%. However, with interest rates back on the rise and consumer spending accelerating, shares have already started to reverse these declines, and Bank of America shares have risen 32% so far in 2021.</p>\n<p><b>The Coca-Cola Company</b></p>\n<p>Berkshire Hathaway's stake in Coca-Cola (KO) remained unchanged between 2019 and 2020 at 400 million shares, offering 9.3% ownership in the beverage giant. Buffett has been a long-time investor in the firm, having first purchased shares in Berkshire's portfolio in 1988. It has comprised a significant portion of the firm's total holdings and mark value value ever since.</p>\n<p>This long-term investment has paid off for the company, with the market value of the shares held totaling $21.9 billion at the end of 2020. Berkshire spent just under $1.3 billion building its stake in Coca-Cola.</p>\n<p>While Berkshire's overall return on its investment in Coca-Cola has been formidable, the stock did underperform the broader market in 2020. Coca-Cola shares declined 0.9% during the year as a dearth of live events and concessions weighed on sales, though the stock did still eke out a total return of 2.44% during the year with reinvested dividends. Shares have extended a run of underperformance in 2021, with the stock falling 1.5% so far this year.</p>\n<p><b>American Express</b></p>\n<p>Berkshire Hathaway held 151,610,700 shares of American Express (AXP) as of the end of 2020, with the stock comprising another of the firm's long-standing investments. Berkshire began building its stake nearly six decades ago, paying a total of just $1.29 billion to amass a stake worth $18.33 billion at the end of 2020.</p>\n<p>As a business relying heavily on both consumer and corporate spending, however, American Express' suffered a blow in 2020, with its stock dipping 2.9%.</p>\n<p>While Buffett has characterized Berkshire's holdings of marketable stocks as a \"collection of businesses\" in which he shares in long-term prosperity but does not control operations, that hasn't stopped him from imparting advice to executives at some of his top-held companies — especially during the nadir in business and economic activity during the pandemic.</p>\n<p>\"I talked to our largest shareholder, Warren Buffett, and I've talked to him during this time, the one thing he has and will continue to always point out to us is that the brand is special,\" American Express CEO Stephen Squeri said during an analyst day presentation in mid-March 2020. \"And that brand needs to be cared for, the brand needs to be invested in and we will continue to do so through tough times and through the good times.\"</p>\n<p>More recently, however, American Express's operating results and stock have picked back up. The stock outperformed the S&amp;P 500 with a rise of 25% for the year-to-date. And Squeri saidin a fourth-quarter updatethat non-travel and entertainment spend exceeded pre-COVID levels for a second straight quarter, and that trends overall have \"continued to steadily improve,\" despite some lingering impacts from the pandemic.</p>\n<p><b>Verizon Communications</b></p>\n<p>Verizon Communications (VZ), the parent company of Yahoo Finance, was one of Berkshire's new purchases in the second half of 2020.</p>\n<p>Berkshire revealed it amassed a stake of 146,716,496 shares of the telecommunications giant last year, good for a 3.5% ownership of the company.</p>\n<p>The holding was worth $8.62 billion as of year-end, representing one of several major investments Berkshire held below cost, which in this case came in at $8.69 billion. The decline likely would have been greater had Berkshire purchased the sizable stake earlier, however, with Verizon's stock having declined 4.3% excluding reinvested dividends over the the full-year 2020.</p>\n<p>But even given the pandemic, Verizon's business held up relatively strongly. Full-year 2020 sales edged down by just 3%, and adjusted EBITDA was flat year-over-year. Still, the stock has declined by 4% for 2021-to-date, or by 2% with reinvested dividends.</p>\n<p><b>Moody's Corporation</b></p>\n<p>Berkshire Hathaway had a 13.2% ownership stake in Moody's Corporation (MCO) at the end of 2020, with 24,669,778 shares worth a total of $7.16 billion. That generated a notable return for Berkshire, with the cost of building this stake amounting to just $248 million. Berkshire first held shares of Moody's Corporation in 2000.</p>\n<p>The credit rating agency outperformed the S&amp;P 500 in 2020 and has since performed about in-line with the market during the COVID-19 recovery. Shares rose by 22% over the course of 2020 and have increased by 12.5% for the year-to-date.</p>\n<p><b>U.S. Bancorp</b></p>\n<p>U.S. Bancorp (USB) was one of a number of holdings Berkshire Hathaway trimmed during the pandemic.</p>\n<p>The firm's stake in the parent company of U.S. Bank National Association was reduced to 148,176,166 shares by year-end 2020, compared to 149,497,787 in 2019. However, Berkshire Hathaway stopped short of fully exiting its position in the firm, as it did with some other big banks. Berkshire's position in U.S. Bancorp was worth just over $6.9 billion in year-end 2020, compared to total cost of $5.6 billion.</p>\n<p>As was the case for many financial institutions during the pandemic, U.S. Bancorp's stock came under pressure in the low-rate environment of 2020, but has since rebounded. Shares slid by 21.4% in 2020, but have so far risen more than 25% for the year-to-date.</p>\n<p><b>BYD</b></p>\n<p>Shenzhen-based BYD Co. (BYDDF) marks one of just a couple non-U.S. companies in Berkshire Hathaway's portfolio as of the end of 2020. The electric-vehicle manufacturer's stock was also the best-performing in Berkshire's portfolio during the pandemic on a price-appreciation basis, consistent with the outperformance among tech and growth stocks seen over the course of last year in the broader market. In fact, the market value of Berkshire's BYD Co. stake was more than double that of its other major auto-related position in General Motors (GM).</p>\n<p>Berkshire purchased the entirety of his 225 million share stake in BYD back in 2008 for $232 million, afterBuffett's business partner Charlie Munger toutedthe vision of its founder Wang Chuanfu. The value of that stake ballooned to $5.9 billion at the end of 2020. Shares of BYD surged by 432% in 2020 alone, though they have dipped by 13.5% for the year-to-date as some of the exuberance around electric-vehicle stocks moderated at the start of this year.</p>\n<p><b>Chevron</b></p>\n<p>Berkshire Hathaway pounced at the opportunity to purchase Chevron (CVX) during a dip in oil prices and energy stocks last year, snapping up 48,498,965 million shares at a total cost of $4.02 billion. This represented 2.5% of shares outstanding for the stock.</p>\n<p>By year-end, the market value of Berkshire's stake increased slightly to about $4.1 billion, with energy prices back on the rise following the worst points of spring 2020. Chevron's stock slid 30% between year-end 2019 and year-end 2020.</p>\n<p>Berkshire's investment has already begun to appreciate in value in the early months of 2021, with energy as the best-performing sector in the S&amp;P 500 for the year-to-date. Chevron shares have risen 21.6% so far this year for a price appreciation nearly double that of the broader market, not including reinvested dividends.</p>\n<p><b>Charter Communications</b></p>\n<p>Charter Communications (CHTR) marked another holding Berkshire Hathaway trimmed in 2020. In August of last year, Berkshire reported it had cut its stake by 4% to a total of about 5.2 million shares.</p>\n<p>The sale still left Berkshire with a 2.7% stake in the company, and holdings worth $3.45 billion by year-end 2020, at a total cost of just $904 million. Berkshire had beenaccumulating its stake in Charter since 2014.</p>\n<p>Shares of Charter Communications rose 36% in 2020, but have given back some of these gains after dipping 1.2% so far in 2021.</p>\n<p><i>* This analysis excludes Berkshire Hathaway's Kraft Heinz holding of 325,442,152 shares, since this is held using a different accounting method. Berkshire reported that the market value of these shares was $11.3 billion as of December 31, 2020.</i></p>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s how Warren Buffett’s top investments fared during the pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s how Warren Buffett’s top investments fared during the pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html><strong>Yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.\nThe famed stock portfolio run by billionaire investor Warren Buffett ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVX":"雪佛龙","KO":"可口可乐","002594":"比亚迪","MCO":"穆迪","BAC":"美国银行","CHTR":"特许通讯","01211":"比亚迪股份","VZ":"威瑞森","USB":"美国合众银行","AXP":"美国运通","AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/heres-how-warren-buffetts-top-investments-fared-during-the-pandemic-151003576.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104198438","content_text":"Plenty of Berkshire Hathaway's (BRK-A,BRK-B) top stock picks have been home runs during and prior to the COVID-19 pandemic.\nThe famed stock portfolio run by billionaire investor Warren Buffett ballooned to a value of $281.17 billion by the end of 2020, or more than double the cumulative cost of building these stakes at $108.62 billion, according toBerkshire's latest annual shareholder letter.The value of the portfolio's total equity investments carried at market was up 13.4% compared to year-end 2019. However, Berkshire's own stock underperformed the broader market over that time period: The S&P 500 rose 16.3% in 2020, without including reinvested dividends, while Berkshire's Class B shares increased 2.4%.\nBerkshire's stock performance in 2020 relative to the broader market, however, belies what has been, in aggregate, decades of outperformance for the Omaha, Nebraska-based company. Berkshire Hathaway's annual compounded gain between 1965 and 2020 was 20%, versus just 10.2% for the S&P 500. And the firm's cumulative returns over that period have been a whopping 2,810,526% to the S&P 500's 23,454%.\nOn May 1, Buffett and long-time business partner Charlie Munger will hold Berkshire Hathaway's annual shareholder meeting in Los Angeles. This may serve as a forum for the pair to discuss additional investments purchased and sold in the first months of 2021, ahead of formal 13-F filing reveals later in the month. Last year, Buffett disclosed at the annual meeting thatBerkshire had sold out of its entire interest in the airline stocksAmerican Airlines (AAL), United Airlines (UAL), Delta Air Lines (DAL) and Southwest Airlines (LUV)in the first quarter of 2020.\nHere's how Berkshire's top 10 stock investments by market value fared over the course of the pandemic, based on the stakes disclosed in the Buffett's latest annual shareholder letter.*\nApple\nBuffett pointed to Apple (AAPL) as one of the most valuable assets for Berkshire Hathaway alongside the firm's insurance operation and BNSF Railway, thanks in large part to the iPhone-maker's hefty share repurchases.\nBerkshire owned 907,559,761 shares of Apple as of the end of December for a total market value of $120.4 billion. By contrast, the firm spent just $31 billion accumulating this stake since late 2016.\nThat massive holding — comprising 44% of Berkshire's disclosed assets, according to Bloomberg data — came even after the firm pocketed $11 billion after selling a small portion of its position in 2020.\n\"Despite that sale – voila! – Berkshire now owns 5.4% of Apple,\" Buffett said in the shareholder letter. \"That increase was costless to us,coming about because Applehas continuously repurchased its shares, thereby substantially shrinking the number it now has outstanding.\"\nThough Buffett hashistorically steered away from investing in technology companiesin favor of businesses he has understood more deeply, Berkshire's major holding in Apple proved auspicious during the pandemic, when Big Tech companies led the market higher.\nApple's stock posted a total return of 82% in 2020, outperforming every other \"FAANG\" stock including Facebook, Amazon, Netflix and Alphabet. The run-up has since cooled in early 2021, however, with the stock posting a total return of just 1.4% for the year-to-date through market close on April 27.\nBank of America\nWhile Berkshire Hathaway unloaded many of its bank stock holdings over the course of 2020, it increased its stake in Bank of America (BAC).\nThe firm held 1,032,952,006 shares of Bank of America as of the end of 2020, after adding 85.1 million shares in the third quarter alone. This gave Berkshire Hathaway an ownership stake of 11.9%.\nBy the end of last year, the value of that holding was worth $31.3 million, and cost $14.6 million to amass.\nThe increase in the size of Berkshire Hathaway's Bank of America holding bucked the trend of the other bank stocks in the portfolio last year. Berkshire cut its holdings of Wells Fargo (EFC) from 345.7 million shares at year-end 2019 to 52.4 million by year-end 2020, and completely exited its holdings in JPMorgan Chase (JPM) and M&T Bank Corp (MTB).\nWith interest rates sliding amid ultra-accommodative monetary policy during the pandemic, bank stocks were among the worst performers last year. Bank of America shares fell nearly 14% in 2020, underperforming against both the S&P 500 and S&P 500 financials sector, which dropped just 4.1%. However, with interest rates back on the rise and consumer spending accelerating, shares have already started to reverse these declines, and Bank of America shares have risen 32% so far in 2021.\nThe Coca-Cola Company\nBerkshire Hathaway's stake in Coca-Cola (KO) remained unchanged between 2019 and 2020 at 400 million shares, offering 9.3% ownership in the beverage giant. Buffett has been a long-time investor in the firm, having first purchased shares in Berkshire's portfolio in 1988. It has comprised a significant portion of the firm's total holdings and mark value value ever since.\nThis long-term investment has paid off for the company, with the market value of the shares held totaling $21.9 billion at the end of 2020. Berkshire spent just under $1.3 billion building its stake in Coca-Cola.\nWhile Berkshire's overall return on its investment in Coca-Cola has been formidable, the stock did underperform the broader market in 2020. Coca-Cola shares declined 0.9% during the year as a dearth of live events and concessions weighed on sales, though the stock did still eke out a total return of 2.44% during the year with reinvested dividends. Shares have extended a run of underperformance in 2021, with the stock falling 1.5% so far this year.\nAmerican Express\nBerkshire Hathaway held 151,610,700 shares of American Express (AXP) as of the end of 2020, with the stock comprising another of the firm's long-standing investments. Berkshire began building its stake nearly six decades ago, paying a total of just $1.29 billion to amass a stake worth $18.33 billion at the end of 2020.\nAs a business relying heavily on both consumer and corporate spending, however, American Express' suffered a blow in 2020, with its stock dipping 2.9%.\nWhile Buffett has characterized Berkshire's holdings of marketable stocks as a \"collection of businesses\" in which he shares in long-term prosperity but does not control operations, that hasn't stopped him from imparting advice to executives at some of his top-held companies — especially during the nadir in business and economic activity during the pandemic.\n\"I talked to our largest shareholder, Warren Buffett, and I've talked to him during this time, the one thing he has and will continue to always point out to us is that the brand is special,\" American Express CEO Stephen Squeri said during an analyst day presentation in mid-March 2020. \"And that brand needs to be cared for, the brand needs to be invested in and we will continue to do so through tough times and through the good times.\"\nMore recently, however, American Express's operating results and stock have picked back up. The stock outperformed the S&P 500 with a rise of 25% for the year-to-date. And Squeri saidin a fourth-quarter updatethat non-travel and entertainment spend exceeded pre-COVID levels for a second straight quarter, and that trends overall have \"continued to steadily improve,\" despite some lingering impacts from the pandemic.\nVerizon Communications\nVerizon Communications (VZ), the parent company of Yahoo Finance, was one of Berkshire's new purchases in the second half of 2020.\nBerkshire revealed it amassed a stake of 146,716,496 shares of the telecommunications giant last year, good for a 3.5% ownership of the company.\nThe holding was worth $8.62 billion as of year-end, representing one of several major investments Berkshire held below cost, which in this case came in at $8.69 billion. The decline likely would have been greater had Berkshire purchased the sizable stake earlier, however, with Verizon's stock having declined 4.3% excluding reinvested dividends over the the full-year 2020.\nBut even given the pandemic, Verizon's business held up relatively strongly. Full-year 2020 sales edged down by just 3%, and adjusted EBITDA was flat year-over-year. Still, the stock has declined by 4% for 2021-to-date, or by 2% with reinvested dividends.\nMoody's Corporation\nBerkshire Hathaway had a 13.2% ownership stake in Moody's Corporation (MCO) at the end of 2020, with 24,669,778 shares worth a total of $7.16 billion. That generated a notable return for Berkshire, with the cost of building this stake amounting to just $248 million. Berkshire first held shares of Moody's Corporation in 2000.\nThe credit rating agency outperformed the S&P 500 in 2020 and has since performed about in-line with the market during the COVID-19 recovery. Shares rose by 22% over the course of 2020 and have increased by 12.5% for the year-to-date.\nU.S. Bancorp\nU.S. Bancorp (USB) was one of a number of holdings Berkshire Hathaway trimmed during the pandemic.\nThe firm's stake in the parent company of U.S. Bank National Association was reduced to 148,176,166 shares by year-end 2020, compared to 149,497,787 in 2019. However, Berkshire Hathaway stopped short of fully exiting its position in the firm, as it did with some other big banks. Berkshire's position in U.S. Bancorp was worth just over $6.9 billion in year-end 2020, compared to total cost of $5.6 billion.\nAs was the case for many financial institutions during the pandemic, U.S. Bancorp's stock came under pressure in the low-rate environment of 2020, but has since rebounded. Shares slid by 21.4% in 2020, but have so far risen more than 25% for the year-to-date.\nBYD\nShenzhen-based BYD Co. (BYDDF) marks one of just a couple non-U.S. companies in Berkshire Hathaway's portfolio as of the end of 2020. The electric-vehicle manufacturer's stock was also the best-performing in Berkshire's portfolio during the pandemic on a price-appreciation basis, consistent with the outperformance among tech and growth stocks seen over the course of last year in the broader market. In fact, the market value of Berkshire's BYD Co. stake was more than double that of its other major auto-related position in General Motors (GM).\nBerkshire purchased the entirety of his 225 million share stake in BYD back in 2008 for $232 million, afterBuffett's business partner Charlie Munger toutedthe vision of its founder Wang Chuanfu. The value of that stake ballooned to $5.9 billion at the end of 2020. Shares of BYD surged by 432% in 2020 alone, though they have dipped by 13.5% for the year-to-date as some of the exuberance around electric-vehicle stocks moderated at the start of this year.\nChevron\nBerkshire Hathaway pounced at the opportunity to purchase Chevron (CVX) during a dip in oil prices and energy stocks last year, snapping up 48,498,965 million shares at a total cost of $4.02 billion. This represented 2.5% of shares outstanding for the stock.\nBy year-end, the market value of Berkshire's stake increased slightly to about $4.1 billion, with energy prices back on the rise following the worst points of spring 2020. Chevron's stock slid 30% between year-end 2019 and year-end 2020.\nBerkshire's investment has already begun to appreciate in value in the early months of 2021, with energy as the best-performing sector in the S&P 500 for the year-to-date. Chevron shares have risen 21.6% so far this year for a price appreciation nearly double that of the broader market, not including reinvested dividends.\nCharter Communications\nCharter Communications (CHTR) marked another holding Berkshire Hathaway trimmed in 2020. In August of last year, Berkshire reported it had cut its stake by 4% to a total of about 5.2 million shares.\nThe sale still left Berkshire with a 2.7% stake in the company, and holdings worth $3.45 billion by year-end 2020, at a total cost of just $904 million. Berkshire had beenaccumulating its stake in Charter since 2014.\nShares of Charter Communications rose 36% in 2020, but have given back some of these gains after dipping 1.2% so far in 2021.\n* This analysis excludes Berkshire Hathaway's Kraft Heinz holding of 325,442,152 shares, since this is held using a different accounting method. Berkshire reported that the market value of these shares was $11.3 billion as of December 31, 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100430961,"gmtCreate":1619627089353,"gmtModify":1704727092931,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/100430961","repostId":"1196474090","repostType":4,"repost":{"id":"1196474090","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619623392,"share":"https://ttm.financial/m/news/1196474090?lang=&edition=fundamental","pubTime":"2021-04-28 23:23","market":"us","language":"en","title":"Uber app in U.S. to enable users to book vaccines and rental cars","url":"https://stock-news.laohu8.com/highlight/detail?id=1196474090","media":"Reuters","summary":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. custo","content":"<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber app in U.S. to enable users to book vaccines and rental cars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber app in U.S. to enable users to book vaccines and rental cars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-28 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196474090","content_text":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.\nCustomers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.\nThe feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.\nFor Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.\nThe company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.\nFrom Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.\nIn May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.\nUber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.\nUber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.","news_type":1},"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376955276,"gmtCreate":1619083157295,"gmtModify":1704719364539,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/376955276","repostId":"1134663439","repostType":4,"repost":{"id":"1134663439","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619082614,"share":"https://ttm.financial/m/news/1134663439?lang=&edition=fundamental","pubTime":"2021-04-22 17:10","market":"us","language":"en","title":"Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1134663439","media":"Benzinga","summary":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have team","content":"<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-22 17:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SQ":"Block"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134663439","content_text":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.What Happened: Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.Square is heavily invested in Bitcoin. Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchangeCoinbase Global Inc.(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.Why It Matters: The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation.Bank of America analyst Francisco Blanchcriticized Bitcoin in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.Microsoft Corporation (NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887583775,"gmtCreate":1632064306797,"gmtModify":1676530694708,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887583775","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://ttm.financial/m/news/2153678132?lang=&edition=fundamental","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}